TRIANA Biomedicines Announces Participation in Goldman Sachs’ Healthcare Private Company Conference
Lexington, MA – October 19, 2026 – TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that Patrick Trojer, PhD, President and Chief Executive Officer of TRIANA Biomedicines will participate in a panel discussion on “Expanding the Universe of Druggable Oncology Targets” at the Goldman Sachs’ Healthcare Private Company Conference at 2:00 PM EST on October 19, 2026 in New York, New York.
About TRIANA Biomedicines, Inc.
TRIANA Biomedicines is a private biotechnology company, headquartered in Lexington, Massachusetts, focused on building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by bespoke chemical libraries, deep biochemical and biological mechanistic insights in addition to high resolution structural biology. TRIANA’s target-first and proximity-first approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile disease targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients.
Contact